U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent (NYSE:LLY)

INDIANAPOLIS, Aug. 25, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta^® (pemetrexed for injection).

In the case of Eli Lilly and Company v. Teva Parenteral Medicines, Inc., et al., the court ruled that the vitamin regimen patent would be infringed by the generic challengers' proposed products. The patent provides intellectual property protection for Alimta until May 2022.  In March 2014, the court previously upheld the validity of the vitamin regimen patent. The Alimta compound patent remains in force through early 2017.

U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent (NYSE:LLY)